PME, IDX and DOC: Three ASX Digital Healthcare Stocks on the Radar This September

Sonal Goyal

14 September 2026 05:50 PM AEST

PME, IDX and DOC: Three ASX Digital Healthcare Stocks on the Radar This September

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Pro Medicus Limited (ASX:PME), Integral Diagnostics Limited (ASX:IDX) and Doctor Care Anywhere Group PLC (ASX:DOC) provide exposure to different areas of digital healthcare. Pro Medicus develops medical imaging software, Integral Diagnostics operates diagnostic imaging clinics across Australia and New Zealand, while Doctor Care Anywhere provides digital-first primary care services in the United Kingdom.

Their latest financial results show different Business profiles. Pro Medicus combines high-margin software Revenue with a debt-free balance sheet, Integral Diagnostics operates at a much larger revenue scale following its expanded imaging network, while Doctor Care Anywhere is progressing toward a more mature cash-generative telehealth model.

Digital Healthcare Outlook

Digital healthcare businesses can generate revenue through software licensing, diagnostic services or virtual consultations. Their financial performance depends on different drivers, including contract implementation, patient volumes, reimbursement and operating efficiency.

For investors, profitability, margins and cash generation remain important measures alongside headline revenue growth, particularly where companies are investing in expansion or integrating acquisitions.

Pro Medicus Limited (ASX:PME)

Company Profile

Pro Medicus is a medical imaging software company best known for its Visage platform.

The company provides cloud-based radiology viewing and workflow technology to large healthcare systems, particularly in the United States.

Its commercial model is largely based on multi-year contracts and transaction-based licensing, allowing revenue to increase as customer imaging volumes grow.

FY2026 Financial Performance

Pro Medicus Limited (ASX:PME) reported FY2026 revenue of AUD 261.7 million.

Net profit after tax reached AUD 144.7 million.

The company delivered an EBIT Margin of 74.9%, reflecting the high-margin characteristics of its software model.

Cash and financial Assets stood at AUD 252.3 million at 30 June 2026, with no Debt reported.

The company also secured a substantial amount of new contracted business during FY2026, which may support revenue as new implementations progressively go live.

Outlook and Risks

Pro Medicus remains focused on implementing existing contracts and securing additional healthcare-system customers.

The main risks are execution around major deployments, customer concentration in the United States and the potential impact of currency movements.

A high-margin business model also means future Earnings expectations remain closely linked to maintaining contract momentum.

Integral Diagnostics Limited (ASX:IDX)

Company Profile

Integral Diagnostics operates diagnostic imaging clinics across Australia and New Zealand.

Its services include X-ray, ultrasound, CT, MRI and nuclear medicine, supported by a growing teleradiology operation.

The business expanded materially following the integration of Capitol Health.

FY2026 Financial Performance

Integral Diagnostics Limited (ASX:IDX) reported FY2026 revenue of AUD 788.7 million.

Operating EBITDA reached AUD 164.8 million, representing a margin of 20.9%.

Operating net profit after tax was AUD 47.4 million, while statutory net profit after tax was AUD 22.0 million.

Net debt stood at AUD 298.9 million, with Leverage improving to 2.3 times EBITDA.

The company also had AUD 117.0 million of undrawn committed facilities at year-end.

Integral Diagnostics declared a fully franked final Dividend of 6 cents per share.

FY2027 Outlook

Management is targeting continued revenue growth, an EBITDA margin above 21% and further reduction in leverage.

The company is now moving beyond the main integration phase of its enlarged imaging network and focusing more heavily on organic growth and operating efficiencies.

Risks

Integral Diagnostics remains exposed to radiologist availability, labour costs and reimbursement conditions.

Its debt position also means continued earnings growth and cash generation will be important to further de-gearing.

Capital expenditure remains necessary because diagnostic imaging is equipment intensive.

Doctor Care Anywhere Group PLC (ASX:DOC)

Company Profile

Doctor Care Anywhere is a UK digital healthcare provider offering virtual general practitioner consultations and related clinical services.

The company primarily works with private medical insurers and corporate customers while also expanding into additional areas such as weight management.

Its securities trade on the ASX as CHESS Depositary Interests.

1H 2026 Financial Performance

For the six months ended 30 June 2026, Doctor Care Anywhere Group PLC (ASX:DOC) reported revenue of GBP 20.4 million.

EBITDA reached GBP 2.6 million, representing an EBITDA margin of 12.8%.

Net profit attributable to members was GBP 0.6 million.

Cash stood at GBP 7.7 million at 30 June 2026, while free Cash Flow improved materially compared with the prior corresponding period.

No Interim Dividend was declared.

Outlook and Risks

Doctor Care Anywhere is focused on improving revenue Diversification and building on its increasingly profitable operating model.

Expansion into additional healthcare services may provide new revenue opportunities, although the company remains dependent on insurer relationships for a meaningful portion of its business.

Customer concentration, regulatory oversight of remote healthcare and relatively modest consultation growth remain key risks.

Risks to Watch

Pro Medicus faces execution and customer-concentration risk despite its high margins and substantial cash position.

Integral Diagnostics faces labour, reimbursement and leverage risks as it operates a large capital-intensive imaging network.

Doctor Care Anywhere remains smaller and more dependent on a limited number of commercial relationships, although its profitability and cash position have improved.

Across all three companies, healthcare regulation and payer arrangements remain important influences on financial outcomes.

What Investors May Watch Through the Rest of 2026

For Pro Medicus, investors may monitor contract implementations, new customer wins and transaction-revenue growth.

For Integral Diagnostics, attention may remain on organic imaging volumes, EBITDA margin progression and debt reduction.

For Doctor Care Anywhere, investors may focus on revenue diversification, cash generation and the contribution from newer healthcare services.

The three companies therefore represent different digital healthcare models: Pro Medicus operates a high-margin enterprise software business, Integral Diagnostics combines physical imaging infrastructure with digital reporting capability, and Doctor Care Anywhere provides virtual healthcare services through a digital platform.

FAQs

Q: What did Pro Medicus report for FY2026?

A:Pro Medicus reported revenue of AUD 261.7 million and net profit after tax of AUD 144.7 million. Cash and financial assets stood at AUD 252.3 million, with no debt reported.

Q: What were Integral Diagnostics' key FY2026 figures?

A:Integral Diagnostics reported revenue of AUD 788.7 million, operating EBITDA of AUD 164.8 million and operating NPAT of AUD 47.4 million.

Q: What did Doctor Care Anywhere report for the first half of 2026?

A:Doctor Care Anywhere reported revenue of GBP 20.4 million, EBITDA of GBP 2.6 million and net profit attributable to members of GBP 0.6 million.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.